<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2070-4909.2018.11.2.077-080</article-id><article-id custom-type="elpub" pub-id-type="custom">farmaec-254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Comments and Opinions</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Комментарии и мнения</subject></subj-group></article-categories><title-group><article-title>Comments to the article by O. Yu. Rebrova and co-authors «Screening at the first stage of periodical health checkup: a systematic review   of long-term results»</article-title><trans-title-group xml:lang="ru"><trans-title>Комментарий к статье О. Ю. Ребровой и соавторов «Скрининги I этапа диспансеризации: систематический обзор долгосрочной эффективности»</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аксёнов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Aksenov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аксёнов Валерий Алексеевич – к. м.н., вице-президент. </p></bio><bio xml:lang="en"><p>Aksenov Valerii Alekseevich – MD, PhD, Vice-president. </p><p>46-2, Dmitrovskoe shosse, Moscow 127238.</p></bio><email xlink:type="simple">v_aksenov@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Межрегиональная общественная организация «Общество специалистов доказательной медицины».<country>Россия</country></aff><aff xml:lang="en">Public Interregional Organization «Society of specialists in evidence based medicine».<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>15</day><month>08</month><year>2018</year></pub-date><volume>11</volume><issue>2</issue><fpage>77</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Aksenov V.A., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Аксёнов В.А.</copyright-holder><copyright-holder xml:lang="en">Aksenov V.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/254">https://www.pharmacoeconomics.ru/jour/article/view/254</self-uri><abstract><p>The aim – to review and analyze the data on the long-term population-based efficiency of the screening procedures and other measures implemented according to Stage 1 periodical health checkup in the Russian Federation (by Order №36ан of 2015).</p><sec><title>Material and methods</title><p>Material and methods. This systematic search was carried out independently by two authors who used four databases: Scientific electronic Library, Cochrane Library, Medline/PubMed, and USPSTF. They looked into systematic reviews quoted by these sources. The criteria of the screening efficacy were the total / specific mortality and disability. The quality of the systematic reviews was assessed by the two authors using the international AMSTAR questionnaire.</p></sec><sec><title>Results</title><p>Results. According to the specific mortality rate, only the fecal occult blood test and the abdominal aorta ultrasonography are found to be efficient as screening methods for certain age and gender groups. The methodological quality of the studied reviews is high or medium to high. As follows from these high quality studies, the efficacy of mammography in female populations remains to be proven. </p></sec></abstract><trans-abstract xml:lang="ru"><p>Цель исследования – систематический поиск и анализ доказательств долгосрочной популяционной эффективности скринингов и других мероприятий, реализуемых в рамках i этапа диспансеризации в Российской Федерации согласно Приказу №36ан от 2015 г.</p><sec><title>Материал и методы</title><p>Материал и методы. Систематический поиск осуществлялся независимо двумя авторами в четырех базах данных: Научная электронная библиотека, The Cochrane Library, Medline/PubMed, USPSTF. Изучаемый тип публикаций – систематические обзоры. Критерии эффективности скрининга: общая и специфическая смертность, инвалидизация. Оценка методологического качества систематических обзоров выполнялась двумя авторами по методике, основанной на международном вопроснике AMSTAR.</p></sec><sec><title>Результаты</title><p>Результаты. Только исследование кала на скрытую кровь и УЗИ брюшной аорты имеют научное обоснование как методы скрининга в определенных половозрастных популяциях по критерию снижения специфической смертности, при этом методологическое качество систематических обзоров является высоким и средним/высоким. Эффективность маммографии в исследованиях высокого методологического качества не доказана. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Диспансеризация</kwd><kwd>скрининг</kwd><kwd>доказательство</kwd><kwd>эффективность</kwd><kwd>смертность</kwd><kwd>систематический обзор</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Periodical health check</kwd><kwd>screening</kwd><kwd>evidence</kwd><kwd>efficacy</kwd><kwd>mortality</kwd><kwd>systematic review</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва О. Ю., Федяева В. К., Омельяновский В. В., Ильин М. А. Cкрининги I этапа диспансеризации: систематический обзор долгосрочной эффективности. Профилактическая медицина. 2017; 3: 5659 / Rebrova O. Yu., Fedyaeva V. K., Omelyanovsky V. V., Ilyin M. A. Stage 1 screenings of periodical health check: A systematic review of long-term efficiency. Profilakticheskaya medicina. 2017; 3: 56-59. DOI: 10.17116/ profmed201720355-59.</mixed-citation><mixed-citation xml:lang="en">Реброва О. Ю., Федяева В. К., Омельяновский В. В., Ильин М. А. Cкрининги I этапа диспансеризации: систематический обзор долгосрочной эффективности. Профилактическая медицина. 2017; 3: 5659 / Rebrova O. Yu., Fedyaeva V. K., Omelyanovsky V. V., Ilyin M. A. Stage 1 screenings of periodical health check: A systematic review of long-term efficiency. Profilakticheskaya medicina. 2017; 3: 56-59. DOI: 10.17116/ profmed201720355-59.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Moyer V. A. U. S. Preventive Services Task Force. Screening for cervical cancer: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2012 Jun 19; 156 (12): 880-91, W312. https://doi.org/10.7326/0003-4819-156-12-201206190-00424.</mixed-citation><mixed-citation xml:lang="en">Moyer V. A. U. S. Preventive Services Task Force. Screening for cervical cancer: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2012 Jun 19; 156 (12): 880-91, W312. https://doi.org/10.7326/0003-4819-156-12-201206190-00424.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Marth C., Landoni F., Mahner S., et al. On behalf of the ESMO Guidelines Committee; Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. July 2017; 28 (4-1): iv72-iv83. https://doi.org/10.1093/annonc/mdx220.</mixed-citation><mixed-citation xml:lang="en">Marth C., Landoni F., Mahner S., et al. On behalf of the ESMO Guidelines Committee; Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. July 2017; 28 (4-1): iv72-iv83. https://doi.org/10.1093/annonc/mdx220.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Siu A. L. U. S. Preventive Services Task Force. Screening for high blood pressure in adults: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2015 Nov 17; 163 (10): 778-86. https://doi.org/10.7326/M15-2223.</mixed-citation><mixed-citation xml:lang="en">Siu A. L. U. S. Preventive Services Task Force. Screening for high blood pressure in adults: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2015 Nov 17; 163 (10): 778-86. https://doi.org/10.7326/M15-2223.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mayor S. Hypertension diagnosis should be based on ambulatory blood pressure monitoring, NICE recommends. BMJ. 2011; 343: d5421. https://doi.org/10.1136/bmj.d5421</mixed-citation><mixed-citation xml:lang="en">Mayor S. Hypertension diagnosis should be based on ambulatory blood pressure monitoring, NICE recommends. BMJ. 2011; 343: d5421. https://doi.org/10.1136/bmj.d5421</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hodgkinson J., Mant J., Martin U., Guo B., Hobbs F. D. R., Deeks J. J., et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011; Jun 24; 342: d3621. https://doi.org/10.1136/bmj.d3621.</mixed-citation><mixed-citation xml:lang="en">Hodgkinson J., Mant J., Martin U., Guo B., Hobbs F. D. R., Deeks J. J., et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011; Jun 24; 342: d3621. https://doi.org/10.1136/bmj.d3621.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Catapano A. L., Graham I., De Backer G., et al.; 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. eur Heart J. 2016 Oct 14; 37 (39): 2999-3058. Epub 2016 Aug 27. PubMed PMID: 27567407.</mixed-citation><mixed-citation xml:lang="en">Catapano A. L., Graham I., De Backer G., et al.; 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. eur Heart J. 2016 Oct 14; 37 (39): 2999-3058. Epub 2016 Aug 27. PubMed PMID: 27567407.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Piepoli M. F., Hoes A. W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). eur Heart J. 2016 Aug 1; 37 (29): 2315-81. https://doi.org/10.1093/eurheartj/ehw106.</mixed-citation><mixed-citation xml:lang="en">Piepoli M. F., Hoes A. W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). eur Heart J. 2016 Aug 1; 37 (29): 2315-81. https://doi.org/10.1093/eurheartj/ehw106.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pinsky P. F., Prorok P. C., Yu K., et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123 (4): 592-599. https://doi.org/10.1002/cncr.30474.</mixed-citation><mixed-citation xml:lang="en">Pinsky P. F., Prorok P. C., Yu K., et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123 (4): 592-599. https://doi.org/10.1002/cncr.30474.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Schroder F. H., Hugosson J., Roobol M. J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384: 2027-35. https://doi.org/10.1016/S01406736(14)60525-0.</mixed-citation><mixed-citation xml:lang="en">Schroder F. H., Hugosson J., Roobol M. J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384: 2027-35. https://doi.org/10.1016/S01406736(14)60525-0.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11 (8): 725-32. https://doi.org/10.1016/S1470-2045(10)70146-7.</mixed-citation><mixed-citation xml:lang="en">Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11 (8): 725-32. https://doi.org/10.1016/S1470-2045(10)70146-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Siu A. L. U. S. Preventive Services Task Force. Screening for Breast Cancer: U. S. Preventive Services Task Force Recommendation Statement. Ann intern Med. 2016 Feb16; 164 (4): 279-96. https://doi.org/10.7326/M15-2886.</mixed-citation><mixed-citation xml:lang="en">Siu A. L. U. S. Preventive Services Task Force. Screening for Breast Cancer: U. S. Preventive Services Task Force Recommendation Statement. Ann intern Med. 2016 Feb16; 164 (4): 279-96. https://doi.org/10.7326/M15-2886.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gøtzsche P. C., Jørgensen K. J. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4; (6): CD001877. https://doi.org/10.1002/14651858.CD001877.pub5.</mixed-citation><mixed-citation xml:lang="en">Gøtzsche P. C., Jørgensen K. J. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4; (6): CD001877. https://doi.org/10.1002/14651858.CD001877.pub5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Siu A. L. U. S. Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U. S. Preventive Services Task Force Recommendation Statement. Ann intern Med. 2015 Dec 1; 163 (11): 861-8. https://doi.org/10.7326/M15-2345.</mixed-citation><mixed-citation xml:lang="en">Siu A. L. U. S. Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U. S. Preventive Services Task Force Recommendation Statement. Ann intern Med. 2015 Dec 1; 163 (11): 861-8. https://doi.org/10.7326/M15-2345.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Moyer V. A. U. S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2012 Oct 2; 157 (7): 512-8. PubMed PMID: 22847227.</mixed-citation><mixed-citation xml:lang="en">Moyer V. A. U. S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2012 Oct 2; 157 (7): 512-8. PubMed PMID: 22847227.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Krogsbøll L. T., Jørgensen K. J., Grønhøj L. C., Gøtzsche P. C. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ. 2012 Nov 20; 345: e7191. https://doi.org/10.1136/bmj.e7191.</mixed-citation><mixed-citation xml:lang="en">Krogsbøll L. T., Jørgensen K. J., Grønhøj L. C., Gøtzsche P. C. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ. 2012 Nov 20; 345: e7191. https://doi.org/10.1136/bmj.e7191.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
